| Mucronulatol from Caribbean propolis exerts cytotoxic effects on human tumor cell lines. | |
| | |
MedLine Citation:
|
PMID: 18538108 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Mucronulatol is one of the most cytotoxic substances present in Caribbean propolis. This work aimed at initially characterizing the biological effects of mucronulatol in cancer cell lines comprehending both wildtype and resistant sublines. MATERIALS AND METHODS: An RP-HPLC technique was employed to separate and purify mucronulatol. IC(50) values were determined using the sulforhodamine B (SRB) proliferation assay. FACS-based cell cycle studies were carried out combining propidium iodide staining and 5-bromo-2'-deoxyuridine incorporation. Cell cycle regulator proteins were detected by Western blotting. The transcription of genes of interest was analyzed using RT-PCR. RESULTS: In MDR1-/MDR3+ cells, mucronulatol exhibited cytotoxicity in the range of 2.7 - 10.2 microg/ml, while no cytotoxic effects were observed in MDR1+ systems at up to 100 microg/ml. Cytometric studies revealed that mucronulatol promoted a global reduction in all cell cycle phases, with a remarkable increase of the apoptotic sub-G1 population. Immunoblotting showed that mucronulatol induced an up-regulation of p21(Cip1) and p27(Kip1) while down-regulating cyclin E and CDK4 in a drug concentration-dependent manner. No effect on topoisomerase I was observed, while we detected an altered expression of topoisomerases II-I+/-/I(2). RT-PCR studies showed that 2-fold the IC(50) in HCT8 colon carcinoma cells was sufficient for altering the expression pattern of genes in this cell line, including topoisomerase I, thymidilate synthase, EGF receptor and c-myc, amongst others. CONCLUSION: Here, we demonstrate for the first time that mucronulatol exerts cytotoxicity in cancer cell lines by targeting the control of cell cycle progression, indicating that the mechanism of action of this compound involves interference with the cell cycle machinery. |
| | |
Authors:
|
D Diaz-Carballo; M Freistã Hler; S Malak; W Bardenheuer; H P Reusch |
Related Documents
:
|
8110498 - Tamoxifen enhances the cytotoxic effects of the nitrosourea fotemustine. results on hum... 12603078 - Toxicity of compound a to c6 rat glioma cells. 22886938 - Heterogeneity of intrinsically photosensitive retinal ganglion cells in the mouse revea... 16980028 - Selective depletion of activated t cells by recombinant immunotoxin containing anti-ctl... 12208758 - Overexpression of wild-type breast cancer resistance protein mediates methotrexate resi... 9566878 - Ras signals to the cell cycle machinery via multiple pathways to induce anchorage-indep... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: International journal of clinical pharmacology and therapeutics Volume: 46 ISSN: 0946-1965 ISO Abbreviation: Int J Clin Pharmacol Ther Publication Date: 2008 May |
Date Detail:
|
Created Date: 2008-06-09 Completed Date: 2008-08-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9423309 Medline TA: Int J Clin Pharmacol Ther Country: Germany |
Other Details:
|
Languages: eng Pagination: 226-35 Citation Subset: IM |
Affiliation:
|
Abteilung Klinische Pharmakologie, Ruhr-Universität Bochum, Germany. david.diaz-carballo@rub.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
chemistry,
isolation & purification*,
pharmacology* Blotting, Western Cell Cycle / drug effects Cell Line, Tumor Cell Proliferation / drug effects Chromatography, High Pressure Liquid Drug Resistance, Neoplasm Humans Indigofera* Isoflavones / chemistry, isolation & purification*, pharmacology* Magnetic Resonance Spectroscopy Mass Spectrometry Reverse Transcriptase Polymerase Chain Reaction West Indies |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Isoflavones; 0/mucronulatol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Bovine colostrum as a biologic in clinical medicine: a review--Part II: clinical studies.
Next Document: A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D...